Could a gut bacteria pill help ARDS patients breathe easier?
NCT ID NCT07646028
First seen Jun 17, 2026 · Last updated Jun 22, 2026 · Updated 1 time
Summary
This early-stage trial tests R-3750, a live biotherapeutic product, in 20 adults with late-stage acute respiratory distress syndrome (ARDS). The main goal is to see if it is safe and tolerable, while also checking for signs of improved lung function and less need for a ventilator. Participants take the drug daily by mouth or through a feeding tube.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE RESPIRATORY DISTRESS SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
R-3750 (a live biotherapeutic product given as capsules or through a feeding tube)
What this could lead to
If safe and effective, R-3750 could offer a new way to reduce ventilator dependence and improve lung function in late-stage ARDS patients.
What could go wrong
This is a very early Phase 1 trial with only 20 participants, so safety and effectiveness are not yet proven. The treatment may not work or could cause side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.